Thymalin: The Thymus Peptide With Forty Years of Clinical Use
A peptide extract from thymus tissue, and one of the oldest compounds in the Khavinson family. It has been prescribed in Russia since the 1980s — which makes it unusually well observed, and unusually easy to overstate.
What Is Thymalin?
Thymalin is a peptide fraction extracted from thymus tissue — one of the first-generation compounds from Vladimir Khavinson’s bioregulator programme, and among the earliest to enter clinical use in the Soviet Union.
The thymus is the organ where T-cells — the immune system’s trained specialists — are educated before release into the body. It is also one of the few organs that visibly shrinks with age: largest in childhood, progressively replaced by fat tissue from adolescence onward, largely inactive by later life. That decline is a well-established fact of human biology, and it is the reason the thymus attracted this kind of research interest in the first place.
The thymus, in plain language: think of it as a training academy for immune cells. Raw recruits arrive, get taught the difference between friend and foe, and graduate into the bloodstream as trained specialists. The academy runs at full capacity when you are young. As the decades pass its buildings are gradually shut down and converted to storage, and fewer graduates come out. Thymalin is studied on the premise of handing that academy back its own operating instructions.
An Extract, Not a Single Peptide
This is the most important technical point about Thymalin, and the one most often glossed over.
Thymalin is a peptide complex — a purified mixture of short peptides with a molecular weight below roughly 10 kDa, obtained from thymus tissue. It is not a single molecule with a written sequence. That distinguishes it from second-generation compounds like Epitalon or Vilon, which are synthesised peptides with defined amino acid sequences.
The practical consequence matters for anyone assessing quality. A chromatographic purity percentage depends on the target, method and calculation basis. It does not by itself establish identity or composition. For a mixture, ask which constituents or specification the reported measurement actually describes.
The synthetic counterpart in this corner of the family is Vilon (Lys-Glu), a defined dipeptide developed from the same thymic research and studied for similar immune endpoints.
What the Research Examines
The cited literature discusses thymic peptide extracts and immune endpoints. The purported 2020 geroprotector paper previously listed here could not be verified and has been removed.
The remaining references include reports and reviews from the originating research programme. They should not be treated as independent confirmation of broad immune or endocrine benefits, and this review does not establish that a supplied extract has the same composition as material used in those studies.
Regulatory Status and What It Does Not Mean
Thymalin has been approved for medical use in Russia since the 1980s, indicated there as an immunomodulator for conditions including viral and bacterial infection, disorders of regenerative processes, and states involving reduced thymic function. Forty years of prescribing represents a genuinely substantial body of clinical observation, and more real-world use than almost any research peptide can claim.
One claim to be careful about. Thymalin is frequently described online as "WHO-approved". It is not. The World Health Organization does not approve medicines in that sense, and Thymalin holds no FDA, EMA or TGA approval. Its approval is Russian, and applies to a specific pharmaceutical product in that country — not to a research-grade material supplied elsewhere.
The other caveat is familiar from the rest of this family: most of the supporting literature is Russian-language and originates from or near the programme that developed the compound. Independent Western replication is limited. That does not make the work wrong; it means the usual outside verification has not yet happened.
Frequently Asked Questions
Compiled by the Southern Pacific Labs research team. Last updated July 2026.
Published References
- Khavinson VKh, Morozov VG. “Peptides of pineal gland and thymus prolong human life.” Neuro endocrinology letters, 2003. PubMed
- Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
- Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
- Goldstein AL, Badamchian M. “Thymosins: chemistry and biological properties in health and disease.” Expert opinion on biological therapy, 2004. PubMed
Related Research Guides
More in Immune & Defence
The whole Khavinson system — one peptide per organ, and the honest state of the evidence.
Read guide →Thymic ImmunomodulatorA defined synthetic thymic peptide, and a useful contrast with an extract like Thymalin.
Read guide →Telomerase ActivatorThe synthesised counterpart of the pineal extract Epithalamin — the same extract-to-synthetic story.
Read guide →